HOUSE_OVERSIGHT_026363.jpg
1.83 MB
Extraction Summary
3
People
9
Organizations
2
Locations
1
Events
2
Relationships
3
Quotes
Document Information
Type:
Web article printout, likely from forbes, with a bates stamp 'house oversight 026363', indicating it is an exhibit from a congressional investigation.
File Size:
1.83 MB
Summary
This document is a printout of an article, likely from Forbes circa 2015, discussing a new cholesterol drug, Praluent. The article details the drug's effectiveness, its high cost ($14,600/year), and the companies involved, such as Regeneron, Sanofi, and Amgen. Although the document has a 'HOUSE_OVERSIGHT' Bates number, its content does not contain any explicit mention of Jeffrey Epstein or related individuals, and its relevance to that case is not apparent from the text itself.
People (3)
| Name | Role | Context |
|---|---|---|
| Steven Nissen | Chairman of Cardiology |
Quoted as the chairman of cardiology at the Cleveland Clinic, commenting on a new class of cholesterol drugs.
|
| Troy Brennan | Chief Medical Officer |
Quoted as the chief medical officer of CVS Caremark, commenting on the high cost of new cholesterol drugs.
|
| Donald Trump |
Mentioned in the title of a linked article: 'Donald Trump And The Decline Of American Character--A Cautionary Tale'.
|
Organizations (9)
| Name | Type | Context |
|---|---|---|
| Cleveland Clinic |
Employer of Steven Nissen.
|
|
| CVS Caremark |
A giant pharmacy benefits manager and employer of Troy Brennan.
|
|
| Amgen |
A pharmaceutical company with a rival medicine to Praluent.
|
|
| FDA (Food and Drug Administration) |
The agency that cleared the drug Praluent for certain patients.
|
|
| Regeneron |
The company that developed Praluent.
|
|
| Sanofi |
The marketing partner of Regeneron for Praluent.
|
|
| Forbes |
The likely publisher of the original article, as indicated by 'Recommended by Forbes'.
|
|
|
Mentioned as a source for a trending article: 'Trending on LinkedIn'.
|
||
| HOUSE_OVERSIGHT |
The source of the Bates stamp 'HOUSE_OVERSIGHT_026363', likely referring to the U.S. House Committee on Oversight and...
|
Locations (2)
| Location | Context |
|---|---|
|
The institution where Steven Nissen is chairman of cardiology.
|
|
|
Mentioned in the titles of linked articles such as 'America's New Manufacturing Boomtowns'.
|
Key Quotes (3)
"Obviously, the class is one of the biggest developments in cardiology in the last decade, that will allow us to treat patients who have been extremely difficult to treat with high levels of LDL cholesterol."Source
— Steven Nissen
(Commenting on the significance of the new drug class.)
HOUSE_OVERSIGHT_026363.jpg
Quote #1
"It's very promising."Source
— Steven Nissen
(Further comment on the new drug class.)
HOUSE_OVERSIGHT_026363.jpg
Quote #2
"If these drugs are used as broadly as they could be used, they are going to be by far the most expensive drug class."Source
— Troy Brennan
(Commenting on the potential high cost of the new drugs.)
HOUSE_OVERSIGHT_026363.jpg
Quote #3
Full Extracted Text
Complete text extracted from the document (2,061 characters)
down the line.
"Obviously, the class is one of the biggest developments in cardiology in the last decade, that will allow us to treat patients who have been extremely difficult to treat with high levels of LDL cholesterol," says Steven Nissen, chairman of cardiology at the Cleveland Clinic. "It's very promising."
But it will also be very expensive, say Troy Brennan, the chief medical officer of CVS Caremark, the giant pharmacy benefits manager."If these drugs are used as broadly as they could be used, they are going to be by far the most expensive drug class," Brennan says.
Praluent, an injection, lowers low-density lipoprotein, the so-called "bad cholesterol", by as much as 60%, far more than the statin drugs alone. It is the first drug to work by targeting a protein called PCSK9. Mutations in the gene that makes it can result in patients having lower cholesterol and a dramatically lower lifetime risk of heart attacks. A rival medicine from Amgen is also expected to be approved soon. The FDA is clearing Praluent for patients with heterozygous familial hypercholesterolemia, a genetic condition that causes high cholesterol, and for people who have heart disease, like those who've had heart attacks or strokes, who are already taking the maximum dose of a statin they can tolerate.
Regeneron and its marketing partner Sanofi say Praluent will have a wholesale cost of $40 a day, or $14,600 a year, for either of two doses, 75 milligrams or 150 mgs. It's likely that insurance companies will get a significant discount, because Amgen and Regeneron will compete by giving the insurers rebates.
Recommended by Forbes
Most Popular
Photos: America's New Manufacturing Boomtowns
Most Popular
Barrel Rolling With A Thrillionaire Entrepreneur
Most Popular
Photos: The 10 Best And Worst States To Make A Living In 2015
Trending on LinkedIn
Donald Trump And The Decline Of American Character--A Cautionary Tale
Most Popular
Photos: America's New Manufacturing Boomtowns
Most Popular
Barrel Rolling With A Thrillionaire Entrepreneur
HOUSE_OVERSIGHT_026363
"Obviously, the class is one of the biggest developments in cardiology in the last decade, that will allow us to treat patients who have been extremely difficult to treat with high levels of LDL cholesterol," says Steven Nissen, chairman of cardiology at the Cleveland Clinic. "It's very promising."
But it will also be very expensive, say Troy Brennan, the chief medical officer of CVS Caremark, the giant pharmacy benefits manager."If these drugs are used as broadly as they could be used, they are going to be by far the most expensive drug class," Brennan says.
Praluent, an injection, lowers low-density lipoprotein, the so-called "bad cholesterol", by as much as 60%, far more than the statin drugs alone. It is the first drug to work by targeting a protein called PCSK9. Mutations in the gene that makes it can result in patients having lower cholesterol and a dramatically lower lifetime risk of heart attacks. A rival medicine from Amgen is also expected to be approved soon. The FDA is clearing Praluent for patients with heterozygous familial hypercholesterolemia, a genetic condition that causes high cholesterol, and for people who have heart disease, like those who've had heart attacks or strokes, who are already taking the maximum dose of a statin they can tolerate.
Regeneron and its marketing partner Sanofi say Praluent will have a wholesale cost of $40 a day, or $14,600 a year, for either of two doses, 75 milligrams or 150 mgs. It's likely that insurance companies will get a significant discount, because Amgen and Regeneron will compete by giving the insurers rebates.
Recommended by Forbes
Most Popular
Photos: America's New Manufacturing Boomtowns
Most Popular
Barrel Rolling With A Thrillionaire Entrepreneur
Most Popular
Photos: The 10 Best And Worst States To Make A Living In 2015
Trending on LinkedIn
Donald Trump And The Decline Of American Character--A Cautionary Tale
Most Popular
Photos: America's New Manufacturing Boomtowns
Most Popular
Barrel Rolling With A Thrillionaire Entrepreneur
HOUSE_OVERSIGHT_026363
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document